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Reviewing co-trimoxazole for HIV-exposed, 
uninfected infants
Most of the 1·3 million infants born to pregnant women 
living with HIV annually avoid HIV acquisition through 
use of maternal antiretroviral therapy (ART) and infant 
ART prophylaxis.1 Despite their HIV-free status, children 
who are HIV-exposed and HIV-uninfected have an 
increased risk of adverse birth, developmental, and 
growth outcomes and increased risks of infection-
related morbidity and mortality that are not fully 
mitigated by breastfeeding.2 In settings with a high 
burden of HIV, where the health-care infrastructure is 
overburdened and where up to one in four infants is 
HIV-exposed and HIV-uninfected, such as South Africa 
and Botswana, modelling studies3 suggest that excess 
mortality in HIV-exposed, HIV-uninfected infants 
increases overall infant mortality rates by approximately 
five deaths per 1000 infants. Clearly, many HIV-exposed, 
HIV-uninfected infants are not surviving and thriving, 
and they need strategies to improve their outcomes.
Since 2000, WHO has recommended co-trimoxazole 
in breastfeeding HIV-exposed, HIV-uninfected infants 
from age 6 weeks until breastfeeding has stopped and 
the infants are confirmed not to be infected with HIV.4 
At the time, this approach targeted morbidity and 
mortality in HIV-infected infants, when HIV diagnostics 
(access to polymerase chain reaction) were poor, the 
risk of infant HIV acquisition was high and accompanied 
by rapid disease progression, early mortality from 
Pneumocystis jirovecii pneumonia was common, and 
there was evidence that co-trimoxazole prevented 
serious bacterial infections in HIV-infected infants and 
children.5 However, there was no such evidence in HIV-
exposed, HIV-uninfected infants. In this context, Brodie 
Daniels and colleagues6 enrolled into their trial HIV-
exposed, HIV-uninfected infants aged 6 weeks whose 
mothers were living with HIV, were actively involved 
in transmission prevention programmes in two clinics 
in South Africa, and were breastfeeding their infants. 
In this study, in The Lancet Global Health, Daniels and 
colleagues randomly assigned the infants to receive co-
trimoxazole or no co-trimoxazole, and they assessed 
the difference in mortality and infectious complications, 
specifically severe diarrhoea and pneumonia.6 Their 
finding that no co-trimoxazole was not inferior to daily 
co-trimoxazole among breastfed HIV-exposed, HIV-
uninfected infants in South Africa supports the findings 
of the Mpepu study,7 in which co-trimoxazole did not 
outperform placebo in breastfed and formula-fed HIV-
exposed, HIV-uninfected infants in Botswana.
The study by Daniel and colleagues is not perfect: the 
most concerning of the study’s limitations were the 
15% loss to follow-up, as a result of which, the authors 
were unable to exclude mortality in these infants. The 
study also had no placebo group, and adherence to 
therapy was not monitored rigorously. Nonetheless, 
the low mortality (0·3% in the co-trimoxazole group 
and 0·2% in the no co-trimoxazole group) and 
relatively few reported cases of severe pneumonia and 
diarrhoea were notable. By contrast, in the Mpepu 
study, 2·4% HIV-exposed, HIV-uninfected infants in 
the co-trimoxazole group and 2·6% of these infants 
in the placebo group died, indicating no difference 
between the groups.7 Daniels and colleagues attribute 
this disparity to more frequent breastfeeding and 
earlier access to conjugated pneumococcal and 
rotavirus vaccines in South Africa than in Botswana.6 
Additionally, most infants in the South African cohort 
had access to safe water and sanitation and, notably, 
the study excluded infants with a serious illness 
before age 6 weeks or those who received antibiotics 
before enrolment, who could represent a higher risk 
subgroup.
The findings in the study by Daniel and colleagues 
and the Mpepu study are context-specific, and a review 
of the current WHO recommendation for HIV-exposed, 
HIV-uninfected infants would need to consider access 
to early infant diagnosis, the strength of the public 
health and vaccination programmes, and the malarial 
status of the country. In the Malawian Breastfeeding, 
Antiretrovirals and Nutrition study,8 which was done 
before the introduction of pneumococcal vaccination, 
co-trimoxazole protected against symptomatic and 
asymptomatic malaria parasitaemia, diarrhoea, and 
pneumonia; the authors postulate that malaria and 
asymptomatic malaria might be drivers of other 
infection-related morbidity and, clearly, the possible 
benefit of malaria prevention would be important.
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In the study by Daniels and colleagues, eight infants 
acquired HIV, four of which infections were related to 
breastfeeding. In settings with low HIV transmission, 
each transmission should be analysed to identify 
opportunities for interventions to move to zero 
transmission. If programmes in malaria non-endemic 
areas stopped routine co-trimoxazole for HIV-exposed, 
HIV-uninfected infants and redirected those resources 
to ensure retention in care and viral suppression of 
nursing women living with HIV and to strengthen 
child health programmes, identification, and linkage 
to care for infants with HIV, some of the mortality of 
HIV-exposed, HIV-uninfected and HIV-infected infants 
might be addressed, and HIV transmission could 
be further reduced while minimising antimicrobial 
resistance. In malaria-endemic areas, similar studies are 
needed in HIV-exposed, HIV-uninfected infants who 
have access to insecticide-treated bed nets, seasonal 
malaria prevention strategies, or malaria vaccines. 
Although the magnitude of the reduction in child 
mortality achieved with community-wide dosing of 
azithromycin is also context-specific, its potential to 
reduce infant mortality and prevent malaria9 through 
programmes that do not require specific resources to 
be targeted to HIV-exposed, HIV-uninfected infants 
is an interesting prospect. In settings with a high 
burden of HIV, future studies that assess strategies 
targeting universal child survival should consider HIV-
exposed, HIV-uninfected infants in their study design 
and compare them to HIV-unexposed, HIV-uninfected 
infants from the same communities receiving the same 
health interventions.
Supporting women living with HIV to continue 
receiving effective ART, improving maternal health, 
breastfeeding, a comprehensive vaccination programme, 
safe water and sanitation, and nutrition support for older 
infants will always be more important than antibiotics to 
reduce child mortality in all children and HIV-exposed, 
HIV-uninfected infants.
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